A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Moderate Hepatic Impairment Clinical Trial

Official title:
A Phase 1, Open-label, Single-dose, Pharmacokinetic Study of Mitapivat in Subjects With Moderate Hepatic Impairment Compared to Matched Healthy Control Subjects With Normal Hepatic Function

Status Completed

Clinical Trial Summary

The primary purpose of this study is to compare the pharmacokinetics (PK) of a single oral dose of mitapivat in participants with moderate hepatic impairment to that in matched healthy control participants with normal hepatic function.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05610657
Study type	Interventional
Source	Agios Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	January 10, 2023
Completion date	July 21, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02871570` - A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function	Phase 1
Completed	`NCT05116826` - Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients	Phase 1
Completed	`NCT04995484` - Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)	Phase 1
Completed	`NCT04223635` - Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants	Early Phase 1
Completed	`NCT01012284` - A Study of TMC207 in Patients With Moderately Impaired Hepatic Function	Phase 1
Completed	`NCT04534699` - Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment	Phase 1
Recruiting	`NCT05224609` - A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction	Phase 1